<DOC>
	<DOC>NCT02694328</DOC>
	<brief_summary>This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.</brief_summary>
	<brief_title>A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Subject has a body mass index (BMI) of 18.030.0 kg/m^2, inclusive, at Visit 1 and Visit 2 Subject meets the DSM5 criteria for a primary diagnosis of schizophrenia Subject is appropriate for outpatient treatment; has no hospitalizations for acute exacerbations of schizophrenia within 6 months before Visit 1 Subject has maintained a stable body weight (change &lt;/= 5%) for at least 3 months prior to Visit 1 based on selfreport Additional criteria may apply Subject has any of the following psychiatric conditions per DSM5 criteria: Diagnosis of schizoaffective disorder or bipolar I or II disorder, or current, untreated or unstable major depressive disorder Clinically significant cognitive difficulties present within the past 2 years that could interfere with participation in the study Druginduced or toxic psychosis Any other psychiatric condition that could interfere with participation in the study Subject poses a current suicide risk at Visit 1 or Visit 2 in the opinion of the investigator Subject has inflammatory bowel disease or any other gastrointestinal disorder associated with weight loss, anorexia nervosa, or binge eating disorder Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>ALKS 3831</keyword>
	<keyword>Samidorphan</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>Weight</keyword>
</DOC>